HQP1351 ( Olverembatinib ) - CML - Chronic Myeloid Leukemia
HQP1351 is an oral, third-generation BCR-ABL TKI targeting a broad spectrum of BCR-ABL mutants, including those with the T315I mutation, to treat drug-resistant CML patients.
CLINICAL TRIALS
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
July 12, 2022, Clinical Trial.gov
Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL)
December 2021, Science Direct
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation
June 28, 2019, Clinical Trial.gov
Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia (CML)
April 12, 2019, Clinical Trial.gov
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
July 12, 2022, Clinical Trial.gov
Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL)
December 2021, Science Direct
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation
June 28, 2019, Clinical Trial.gov
Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia (CML)
April 12, 2019, Clinical Trial.gov
ARTICLES
Olverembatinib Improves EFS in TKI-Resistant Chronic Phase CML
December 13, 2023, Cancer Therapy Advisor
Olverembatinib in Ponatinib-Resistant CML: Considerations for Later-Line Therapy
October 3, 2023, Cancer Therapy Advisor
Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
November 15, 2022, ASH 2022
A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China
November 15, 2022, ASH 2022
Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation
November 15, 2022, ASH 2022
Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1T315I-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)
December 2021, ASH 2021
ASH 2021 | Ascentage Pharma Releases Long-Term Clinical Data of Olverembatinib (HQP1351) in Oral Presentation Demonstrating Efficacy and Safety
December 14, 2021, PR Newswire
ASH 2021 | Ascentage Pharma to Present Three Studies of Olverembatinib (HQP1351), a Novel Drug Candidate for the Treatment of Drug-Resistant Leukemia, in Abstracts Including One Oral Report at ASH Annual Meeting
November 4, 2021, PR Newswire
Priority Review Granted to Ascentage Pharma's New Drug Application for Olverembatinib (HQP1351), the First Third-Generation BCR-ABL Inhibitor in China
October 21, 2020, PrNewswire
FDA Grants Orphan Drug Designation to HQP1351 for Chronic Myeloid Leukemia
May 5, 2020, Cancer Network
FDA Grants HQP1351 Orphan Drug Status in CML
May 4, 2020, OncLive
Ascentage Pharma Releases Updated Data of its Novel BCR-ABL Inhibitor, HQP1351, in an Oral Presentation Nominated for "Best of ASH"
December 10, 2019, Biospace
Ascentage Pharma to Release Updated Data of its Novel, Third-Generation BCR-ABL Inhibitor, HQP1351, in Chinese Chronic Myeloid Leukemia Patients in an Oral Presentation at the 61st American Society of Hematology Annual Meeting
November 14, 2019, PrNewswire
Safety and Efficacy of HQP1351, a 3rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor—Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study
November 29, 2018, Ash Publications
Abstract 1979: HQP1351, a novel multikinase inhibitor in clinical development, overcomes drug resistance for the treatment of gastrointestinal stromal tumors in preclinical models
July 2018, AACR
Olverembatinib Improves EFS in TKI-Resistant Chronic Phase CML
December 13, 2023, Cancer Therapy Advisor
Olverembatinib in Ponatinib-Resistant CML: Considerations for Later-Line Therapy
October 3, 2023, Cancer Therapy Advisor
Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
November 15, 2022, ASH 2022
A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China
November 15, 2022, ASH 2022
Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation
November 15, 2022, ASH 2022
Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1T315I-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)
December 2021, ASH 2021
ASH 2021 | Ascentage Pharma Releases Long-Term Clinical Data of Olverembatinib (HQP1351) in Oral Presentation Demonstrating Efficacy and Safety
December 14, 2021, PR Newswire
ASH 2021 | Ascentage Pharma to Present Three Studies of Olverembatinib (HQP1351), a Novel Drug Candidate for the Treatment of Drug-Resistant Leukemia, in Abstracts Including One Oral Report at ASH Annual Meeting
November 4, 2021, PR Newswire
Priority Review Granted to Ascentage Pharma's New Drug Application for Olverembatinib (HQP1351), the First Third-Generation BCR-ABL Inhibitor in China
October 21, 2020, PrNewswire
FDA Grants Orphan Drug Designation to HQP1351 for Chronic Myeloid Leukemia
May 5, 2020, Cancer Network
FDA Grants HQP1351 Orphan Drug Status in CML
May 4, 2020, OncLive
Ascentage Pharma Releases Updated Data of its Novel BCR-ABL Inhibitor, HQP1351, in an Oral Presentation Nominated for "Best of ASH"
December 10, 2019, Biospace
Ascentage Pharma to Release Updated Data of its Novel, Third-Generation BCR-ABL Inhibitor, HQP1351, in Chinese Chronic Myeloid Leukemia Patients in an Oral Presentation at the 61st American Society of Hematology Annual Meeting
November 14, 2019, PrNewswire
Safety and Efficacy of HQP1351, a 3rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor—Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study
November 29, 2018, Ash Publications
Abstract 1979: HQP1351, a novel multikinase inhibitor in clinical development, overcomes drug resistance for the treatment of gastrointestinal stromal tumors in preclinical models
July 2018, AACR
See also Mutation T315I
